2018
DOI: 10.1172/jci94586
|View full text |Cite
|
Sign up to set email alerts
|

Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

5
116
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 170 publications
(131 citation statements)
references
References 89 publications
5
116
1
Order By: Relevance
“…Recent studies have shown that some chemotherapeutic drugs could induce tumor cell ICD, which could potentially elicit or enhance an antitumor immune response (13)(14)(15)(16)(17). The common features of ICD are upregulated expression or release of damage-associated molecular patterns (DAMPs) by the dying tumor cells (13).…”
Section: Introductionmentioning
confidence: 99%
“…Recent studies have shown that some chemotherapeutic drugs could induce tumor cell ICD, which could potentially elicit or enhance an antitumor immune response (13)(14)(15)(16)(17). The common features of ICD are upregulated expression or release of damage-associated molecular patterns (DAMPs) by the dying tumor cells (13).…”
Section: Introductionmentioning
confidence: 99%
“…Then, DCs acquire high capability to migrate, to phagocytose dying cells, to process more efficiently caspase-cleaved cellular proteins (i.e., NM-neoAgs), and to cross-prime CD8 + T cells that can provide tumor control 35,38,41,42 , on the one hand, and immunopathology in various forms of chronic inflammatory diseases, on the other hand 37,[43][44][45][46][47][48] . In addition, several studies found that ICD synergizes with ICB therapy to further improve T cell responses against different tumors, proposing hence the hypothesis that ICD converts tumor cells into endogenous vaccine and boosts the ICB effects [49][50][51][52][53][54] . However, despite the large body of evidences on how ICD occurs, few evidences have been reported about the nature of antigens becoming immunogenic upon ICD 41,42 .…”
mentioning
confidence: 99%
“…In murine syngeneic tumor models, use of dinaciclib increased immunogeneic properties of tumor cells, including early expression of type I interferon response genes, and increased expression of PD-1. When dinaciclib was combined with an anti-PD-1 antibody, T-cell and APC activation within the tumor was increased, and antitumor efficacy was improved as compared with either monotherapy (188). The combination of anti-PD-1 (pembrolizumab) and dinaciclib is currently being evaluated in a phase 1 trial in patients with hematologic malignancies (KEYNOTE-155, NCT02684617).…”
Section: Combination Therapy Utilizing Cdk9 Inhibitionmentioning
confidence: 99%